HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Von Eschenbach Resigning In January With BTC Debate In His Legacy

This article was originally published in The Tan Sheet

Executive Summary

FDA Commissioner Andrew von Eschenbach will return to Texas upon resigning his post Jan. 20, leaving a legacy that includes restarting discussions on whether a third class of drugs is needed

You may also be interested in...



Frank Torti’s Next 100 Days: Active, Not Just Acting, FDA Commissioner

Frank Torti might not be in charge of FDA for very long, but he seems determined to make his time count

Frank Torti’s Next 100 Days: Active, Not Just Acting FDA Commissioner

Frank Torti might not be in charge of FDA for very long, but he seems determined to make his time count

Von Eschenbach Slated For Nomination As Permanent FDA Head

FDA Acting Commissioner and National Cancer Institute Director Andrew von Eschenbach, MD, will likely be nominated by President George W. Bush as permanent agency head, former FDA Associate Commissioner for External Relations Peter Pitts said March 9

Related Content

Topics

UsernamePublicRestriction

Register

RS137164

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel